Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-621 in moderate to severe atopic dermatitis
NCT06945458Phase 1Completed
- Sponsor
- Kymera Therapeutics
- Start
- Apr 2025
- Primary completion
- Nov 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KT-621 in atopic dermatitis (AD), sponsored by Kymera Therapeutics. Primary endpoints: Adverse Events at 43 days and Treatment-Emergent Potentially Clinically-Significant Abnormalities at 43 days. Started Apr 2025; status: completed.
02
Drugs
KT-621
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06945458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06945458.